Skip to main content

Table 3 Association between Tirofiban and Placebo group

From: Association of tirofiban treatment with outcomes following endovascular therapy in cardioembolic stroke: insights from the RESCUE BT randomized trial

 

Unadjusted model

Adjusted model

Coefficients (95% CI)

P value

Coefficients (95% CI)

P value

3-month mRS score

0.99(0.7,1.39)

0.941

0.91(0.64,1.3)

0.617

3-month mRS score 0–1

1.1(0.73,1.65)

0.651

1(0.63,1.57)

0.994

3-month mRS score 0–2

1.02(0.69,1.51)

0.917

0.97(0.63,1.51)

0.907

3-month mRS score 0–3

0.96(0.64,1.43)

0.828

0.93(0.59,1.47)

0.763

NIHSS 24 h minus baseline

0.3(− 1.49,2.08)

0.745

1.38(0.54,3.49)

0.5

NIHSS 7d minus baseline

1.29(− 1,3.57)

0.27

1.77(0.15,20.34)

0.647

Reperfusion at 48 h

1.36(0.55,3.35)

0.509

1.04(− 1.18,3.25)

0.837

3-month EQ5D5L

− 0.01(− 0.08,0.07)

0.879

0.89(− 1.56,1.91)

0.847

sICH

3.71(1.57,8.77)

0.003

3.85(1.59,9.09)

0.003

Any ICH

1.44(0.96,2.17)

0.079

1.44(0.94,2.19)

0.094

3-month death

1.42(0.85,2.35)

0.177

1.48(0.88,2.52)

0.143

  1. Age, occlusion site, onset to randomization time, Baseline NIHSS, and baseline ASPECTS were adjusted in adjusted model
  2. mRS modified Rankin Scale, EQ-5D-5L EuroQol 5-Dimension 5-Level, sICH symptomatic intracranial hemorrhage
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us